Arcadia Biosciences’ Nitrogen Use Efficiency Trait Completes US Food and Drug Administration Early Food Safety Evaluation
The FDA EFSE review supported the conclusion that the functional protein for the NUE trait, alanine aminotransferase, is safe for consumption by humans and animals and would not raise safety concerns if present in the food supply. The EFSE is applicable to all plant species utilizing Arcadia’s NUE trait.
“Seed products based on the NUE trait are in development for most major
global crops,” said
Conventional crops use only about half of applied nitrogen fertilizer. Much of the remainder moves through the soil and enters ground and surface water systems, or volatilizes into the air as a greenhouse gas 300 times more potent than carbon dioxide. Arcadia’s NUE trait was developed to help farmers increase yields while reducing costly fertilizer usage and improving the environmental footprint of agriculture.
Arcadia and its commercial partners are testing crops with the NUE trait at 16 field trials worldwide in 2015. The trait’s efficacy has been demonstrated in major crops including rice, wheat, barley, sugarcane and canola. To date, three years of independent field trials of NUE in rice have demonstrated an average yield increase of 27 percent in multiple environments. Field trials of NUE wheat lines over multiple locations and crop seasons demonstrated an average yield increase of 10 percent for the leading lines across a range of nitrogen application rates.
“Coupled with the recent regulatory approval of drought tolerant
The data provided by Arcadia to the
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements relating to the company's NUE trait and the
regulatory process for such trait. Forward-looking statements are
subject to risks and uncertainties that could cause actual results to
differ materially, and reported results should not be considered as an
indication of future performance. These risks and uncertainties include,
but are not limited to: the company and its partners’ ability to develop
commercial products incorporating its traits, including the NUE trait,
and complete the regulatory review process for such products; the
company’s compliance with laws and regulations that impact the company’s
business, and changes to such laws and regulations; the company’s future
capital requirements and ability to satisfy its capital needs; and the
other risks set forth in the company's filings with the
Arcadia Biosciences, Inc.
Jeff Bergau, +1-312-217-0419